دورية أكاديمية
MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.
| العنوان: | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. |
|---|---|
| المؤلفون: | Martins JRB; Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, Brazil., Moraes LN; Department of Bioprocesses and Biotechnology, School of Agriculture, São Paulo State University (FCA-UNESP), Botucatu 18610-034, Brazil., Cury SS; Department of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (IBB-UNESP), Botucatu 18618-970, Brazil., Capannacci J; Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, Brazil., Carvalho RF; Department of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (IBB-UNESP), Botucatu 18618-970, Brazil., Nogueira CR; Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, Brazil., Hokama NK; Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, Brazil., Hokama POM; Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, Brazil. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2021 Sep 23; Vol. 22 (19). Date of Electronic Publication: 2021 Sep 23. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*therapeutic use , Gene Expression Regulation, Neoplastic/*drug effects , Imatinib Mesylate/*therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics , MicroRNAs/*metabolism, Adult ; Computational Biology ; Down-Regulation/drug effects ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood ; Male ; MicroRNAs/genetics ; Middle Aged ; Protein Interaction Maps/drug effects ; Up-Regulation/drug effects |
| مستخلص: | Chronic myeloid leukemia (CML), a hematopoietic neoplasm arising from the fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9 (BCR-ABL1 oncogene), originates from a small population of leukemic stem cells with extensive capacity for self-renewal and an inflammatory microenvironment. Currently, CML treatment is based on tyrosine kinase inhibitors (TKIs). However, allogeneic hematopoietic stem cell transplantation (HSCT-allo) is currently the only effective treatment of CML. The difficulty of finding a compatible donor and high rates of morbidity and mortality limit transplantation treatment. Despite the safety and efficacy of TKIs, patients can develop resistance. Thus, microRNAs (miRNAs) play a prominent role as biomarkers and post-transcriptional regulators of gene expression. The aim of this study was to analyze the miRNA profile in CML patients who achieved cytogenetic remission after treatment with both HSCT-allo and TKI. Expression analyses of the 758 miRNAs were performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Bioinformatics tools were used for data analysis. We detected miRNA profiles using their possible target genes and target pathways. MiR-125a-3p stood out among the downregulated miRNAs, showing an interaction network with 52 target genes. MiR-320b was the only upregulated miRNA, with an interaction network of 26 genes. The results are expected to aid future studies of miRNAs, residual leukemic cells, and prognosis in CML. |
| References: | Haematologica. 2019 Jan;104(1):82-92. (PMID: 30076175) Genes Cancer. 2013 Sep;4(9-10):342-59. (PMID: 24349632) Oncotarget. 2017 Jan 10;8(2):3666-3682. (PMID: 27705921) Cancers (Basel). 2020 Jul 09;12(7):. (PMID: 32660045) Mol Med Rep. 2019 Jan;19(1):362-374. (PMID: 30431072) Breast Cancer Res. 2010;12(6):R90. (PMID: 21047409) Leuk Res. 2014 Mar;38(3):402-10. (PMID: 24484870) BMC Bioinformatics. 2012 May 01;13:71. (PMID: 22549015) J Pharmacol Exp Ther. 2000 Oct;295(1):139-45. (PMID: 10991971) Adv Drug Deliv Rev. 2015 Jan;81:75-93. (PMID: 25220354) Cell. 2005 Dec 2;123(5):819-31. (PMID: 16325577) Bone Marrow Transplant. 2019 Nov;54(11):1764-1774. (PMID: 30962502) Leukemia. 2009 Jun;23(6):1054-61. (PMID: 19282833) Leukemia. 2020 Apr;34(4):966-984. (PMID: 32127639) Protein Cell. 2013 Mar;4(3):186-96. (PMID: 23483480) Integr Biol (Camb). 2013 Mar;5(3):543-54. (PMID: 23340812) Leukemia. 2014 Apr;28(4):804-12. (PMID: 24072101) PLoS One. 2013 Apr 16;8(4):e61858. (PMID: 23613955) Nat Methods. 2015 Aug;12(8):697. (PMID: 26226356) PLoS One. 2014 May 12;9(5):e97098. (PMID: 24820117) Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. (PMID: 25305453) Nature. 2010 Aug 12;466(7308):835-40. (PMID: 20703300) J Clin Oncol. 2009 Dec 10;27(35):6041-51. (PMID: 19884523) Am J Transl Res. 2016 Feb 15;8(2):955-67. (PMID: 27158382) Leuk Lymphoma. 2019 Mar;60(3):805-811. (PMID: 30188232) Cancer Control. 2009 Apr;16(2):122-31. (PMID: 19337198) Mol Med Rep. 2018 Jan;17(1):939-951. (PMID: 29115476) Ann Hematol. 2015 Apr;94 Suppl 2:S177-86. (PMID: 25814084) Oncogene. 2012 Sep 13;31(37):4150-63. (PMID: 22158050) Genomics Proteomics Bioinformatics. 2014 Apr;12(2):79-91. (PMID: 24755403) Exp Ther Med. 2018 Nov;16(5):4296-4302. (PMID: 30344703) Clin Epigenetics. 2019 Feb 11;11(1):25. (PMID: 30744689) Blood. 2013 Aug 8;122(6):872-84. (PMID: 23803709) Surgery. 2001 Aug;130(2):182-91. (PMID: 11490347) Cancer Res. 1996 Jan 1;56(1):100-4. (PMID: 8548747) Molecules. 2014 Feb 10;19(2):1912-38. (PMID: 24518808) Nat Protoc. 2019 Feb;14(2):482-517. (PMID: 30664679) Cell Stem Cell. 2014 May 1;14(5):673-88. (PMID: 24792119) Cancers (Basel). 2020 Dec 10;12(12):. (PMID: 33321819) Genes Cancer. 2013 Nov;4(11-12):419-26. (PMID: 24386504) Blood. 2011 Jan 20;117(3):755-63. (PMID: 20966165) Asian Pac J Cancer Prev. 2016;17(9):4477-4481. (PMID: 27797264) Semin Hematol. 2010 Oct;47(4):335-43. (PMID: 20875550) Mol Cancer. 2011 Sep 01;10:108. (PMID: 21880154) Braz J Med Biol Res. 2017 Jul 20;50(8):e5891. (PMID: 28746466) Cell Mol Biol (Noisy-le-grand). 2018 Jun 30;64(9):58-63. (PMID: 30030958) Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020) N Engl J Med. 2003 Mar 13;348(11):994-1004. (PMID: 12637609) Front Oncol. 2020 Sep 04;10:1544. (PMID: 33014798) Blood. 1987 Nov;70(5):1382-8. (PMID: 3311203) N Engl J Med. 2002 Feb 28;346(9):683-93. (PMID: 11870247) Nat Rev Clin Oncol. 2016 Feb;13(2):79-91. (PMID: 26573423) Nat Med. 1996 May;2(5):561-6. (PMID: 8616716) Mol Genet Genomic Med. 2019 Sep;7(9):e851. (PMID: 31373443) Blood. 2014 Apr 24;123(17):2645-51. (PMID: 24627528) Blood. 2015 Feb 19;125(8):1302-13. (PMID: 25515961) Semin Hematol. 2010 Oct;47(4):302-11. (PMID: 20875546) Cancer Sci. 2006 Aug;97(8):697-702. (PMID: 16800820) PLoS One. 2013;8(2):e56718. (PMID: 23437222) Biochim Biophys Acta. 2010 Apr;1802(4):396-405. (PMID: 20079433) Mol Cancer. 2018 Feb 19;17(1):40. (PMID: 29455651) Front Immunol. 2018 Jun 15;9:1110. (PMID: 29963039) Am J Hematol. 2018 Mar;93(3):442-459. (PMID: 29411417) J Transl Med. 2013 Feb 07;11:31. (PMID: 23391324) N Engl J Med. 1986 Mar 20;314(12):729-35. (PMID: 3513012) Blood. 2006 Sep 15;108(6):1809-20. (PMID: 16709930) |
| معلومات مُعتمدة: | 2011/50629-7 Fundação de Amparo à Pesquisa do Estado de São Paulo |
| فهرسة مساهمة: | Keywords: allogeneic hematopoietic stem cell transplantation; chronic myeloid leukemia; imatinib mesylate; miR-125a-3p; miR-320b; miRNAs |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (MIRN125 microRNA, human) 0 (MIRN320 microRNA, human) 0 (MicroRNAs) 8A1O1M485B (Imatinib Mesylate) |
| تواريخ الأحداث: | Date Created: 20211013 Date Completed: 20211028 Latest Revision: 20211028 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8508688 |
| DOI: | 10.3390/ijms221910216 |
| PMID: | 34638557 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!